Urea (13C)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Urea (13C) |
| DrugBank ID | DB03904 |
| Brand Names (EU) | Pylobactell |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.61% |
Approved Indication (EMA)
This medicinal product is for diagnostic use only. For in vivo diagnosis of gastroduodenal Helicobacter pylori (H. pylori) infection.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | exanthem (disease) | 99.61% | DL |
| 2 | dermatitis | 98.21% | DL |
| 3 | seborrheic dermatitis | 97.64% | DL |
| 4 | acne keloid | 97.55% | DL |
| 5 | neonatal dermatomyositis | 97.48% | DL |
| 6 | acrodermatitis chronica atrophicans | 97.42% | DL |
| 7 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 97.15% | DL |
| 8 | amyopathic dermatomyositis | 97.12% | DL |
| 9 | hydroa vacciniforme, familial | 96.61% | DL |
| 10 | acne (disease) | 95.53% | DL |
| 11 | dermatitis, atopic | 91.27% | DL |
| 12 | seborrheic keratosis | 90.06% | DL |
| 13 | vulvar inverted follicular keratosis | 86.78% | DL |
| 14 | familial pityriasis rubra pilaris | 75.40% | DL |
| 15 | familial acanthosis nigricans | 75.29% | DL |
| 16 | urticaria, familial localized heat | 74.40% | DL |
| 17 | pityriasis simplex | 73.52% | DL |
| 18 | X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome | 72.62% | DL |
| 19 | severe dermatitis-multiple allergies-metabolic wasting syndrome | 72.62% | DL |
| 20 | van den Bosch syndrome | 72.35% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.